CLINICAL_TRIALS
ClinicalTrials.gov record update
The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04376814
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:40.599801+00:00
- Published At
- 2020-06-16T00:00:00+00:00
- Record Updated At
- 2020-06-16
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["COVID-19", "Favipiravir", "Kaletra", "Hydroxychloroquine", "Lopinavir/Ritonavir"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-06-16"- protocolSection.identificationModule.nctId
"NCT04376814"- protocolSection.identificationModule.officialTitle
"The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["NA"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.